Biovista Inc

Biovista is a privately held biotechnology company in the drug repositioning space. The company uses its 'systematic discovery' COSS™ platform to develop its own pipeline of assets in areas such as CNS and oncology and to offer repositioning and related services to the life-sciences industry. Biovista works with pharma companies on drug life-cycle management and pipeline activism, with generics companies on the development of repositioned super-generics and opportunities in the OTC markets, the FDA and related parties on risk profiling and prediction and with patient advocacy groups on orphan diseases and personalized medicine treatments.